UK Edition
AdvertiseSubmit Company
Pharma JournalEvidence-Based Pharmaceutical Intelligence
CONTRACT MANUFACTURING

Samsung Biologics

S

Samsung Biologics

Contract ManufacturingIncheon, South Korea
Visit Website

About Samsung Biologics

Samsung Biologics is one of the world's largest contract biologics manufacturers, operating from Incheon, South Korea, with a combined bioreactor capacity that ranks it among the highest in the global CDMO industry. Founded in 2011 as a joint venture between Samsung and Quintiles (now IQVIA), the company was established with the explicit ambition of building a world-class biologics manufacturing platform from the ground up.

Large-Scale CDMO Manufacturing

The company operates multiple large-scale manufacturing plants at its Incheon Bio Campus. Its fourth plant, completed in recent years, brought total capacity to a scale that positions Samsung Biologics as a dominant force in contract development and manufacturing for biopharmaceuticals. The facilities support mammalian cell culture processes and are designed to accommodate both clinical and commercial-scale production. A fifth plant is in development as part of the company's continuing capacity expansion strategy.

Samsung Biologics serves a broad roster of global pharmaceutical and biotechnology clients, providing end-to-end services from cell line development through formulation, fill-finish, and quality control. The company holds manufacturing site approvals from major regulatory agencies including the US FDA, EMA, and MFDS, supporting supply into regulated markets worldwide.

Drug Substance & Drug Product Services

Beyond large-molecule drug substance production, Samsung Biologics offers integrated drug product services, including formulation development and aseptic fill-finish manufacturing. Its CDO (contract development organisation) arm provides services spanning analytical development, process development, and regulatory support, enabling clients to move from early-stage biologics programmes through to commercial launch within a single partner relationship.

Listed on the Korea Stock Exchange under the ticker 207940, the company has continued to attract major global partnerships with top-tier pharmaceutical companies, reflecting the scale, quality standards, and reliability of its operations. Samsung Biologics represents South Korea's most prominent contribution to the global biologics CDMO landscape, and its Incheon campus has become a significant hub for biopharmaceutical manufacturing in Asia-Pacific.

Further information is available at samsungbiologics.com.

Similar Companies

More in Contract Manufacturing

R

Recipharm

One of Europe's largest contract development and manufacturing organisations, Recipharm has built its reputation over three decades by taking pharmaceutical products from development through to full commercial manufacture. Founded in Sweden in 1995, the company operates manufacturing sites across Europe, North America, and Asia, giving clients access to a genuinely global production network from a single CDMO partner. Recipharm's capabilities span a broad range of dosage forms, including solid oral, sterile injectables, softgel capsules, liquids, and inhalation products. This breadth allows the company to support both small biotechs bringing a first molecule to market and large pharmaceutical groups seeking to outsource established product lines. The company also offers development services, analytical testing, and packaging, making it possible for clients to manage an entire product lifecycle under one contract. Headquartered in Stockholm, Sweden, Recipharm was previously listed on Nasdaq Stockholm before being taken private following an acquisition by Triton in 2022. It employs several thousand people across its international site network, with facilities operating under relevant regulatory frameworks including those of the EMA and the FDA. The company places particular emphasis on sterile manufacturing, an area of growing demand as the biologics and injectable segments of the pharmaceutical market continue to expand. Its investment in this capacity, alongside ongoing development in complex formulations, positions Recipharm as a relevant partner for innovative as well as generic product programmes. Further information is available at recipharm.com.

View profile
C

Catalent

Catalent is one of the world's largest contract development and manufacturing organisations, supplying drug substance, drug product, and biologics capabilities to pharmaceutical and biotechnology companies across more than 40 countries. Founded in 2007 following the spin-off of Cardinal Health's pharmaceutical technologies and services division, the company built its reputation on solving formulation and delivery challenges that its clients cannot address in-house. Drug Delivery Technologies Catalent's portfolio of proprietary drug delivery platforms is a primary reason manufacturers turn to the company at early development stages. Its Softgel and Optiform technologies serve both small-molecule and biologics formulations, while the OptiMelt and Zydis orally disintegrating tablet platforms address specific bioavailability and patient-compliance challenges. These platforms are applied across therapeutic areas including oncology, rare diseases, consumer health, and central nervous system indications. Biologics & Gene Therapy Manufacturing In recent years, Catalent significantly expanded its biologics manufacturing capacity through a series of acquisitions and facility investments, most notably its purchase of the Bloomington, Indiana biologics site and the acquisition of Paragon Bioservices, which brought substantial cell and gene therapy manufacturing capability. The Harmans, Maryland gene therapy facility became one of the largest commercial-scale viral vector manufacturing sites in North America. This expansion positioned Catalent as a significant partner for advanced therapy developers requiring specialist fill-finish, cell culture, and analytical services. Catalent operates across the United States, Europe, and the Asia-Pacific region, with major sites in Somerset (New Jersey), Brussels, Swindon, and Sydney among others. The company was publicly traded on the New York Stock Exchange under the ticker CTLT before Novo Holdings announced its acquisition in 2024, subsequently transferring a number of its biologics manufacturing sites to Novo Nordisk as part of that transaction. The company serves customers ranging from the world's leading pharmaceutical groups to emerging biotech companies seeking development-stage formulation support through to commercial-scale supply. Further information is available at catalent.com.

View profile
A

Aavis Pharmaceuticals

Aavis Pharmaceuticals operates as a USFDA-approved contract development and manufacturing organisation (CDMO) focused on generic pharmaceuticals, serving partners who require both development expertise and manufacturing scale under a single roof. Headquartered in the Atlanta region, USA, the company is a privately owned subsidiary of Senores Pharmaceuticals Ltd., operating under the legal entity Havix Group Inc. The company's core capability centres on the development and manufacture of immediate-release and controlled-release oral solid dosage forms, with a deliberate emphasis on complex formulations that present competitive barriers to entry. This specialisation in technically demanding molecules positions Aavis as a partner for products that require meaningful research input rather than straightforward replication. Alongside its manufacturing offer, Aavis provides contract research services aimed at developing new formulations for existing drug molecules, with the stated goal of enhancing therapeutic efficiency and improving patient compliance. The organisation describes a management team structured to ensure timely project execution, from early research through to commercial-scale manufacture. As a USFDA-approved facility, the organisation operates within the regulatory framework required for supply into the US market. Its positioning as one of the faster-growing specialist CDMOs in the generic pharmaceuticals segment reflects the breadth of its integrated research-to-manufacture model. Further information is available at aavispharmaceuticals.com.

View profile
AdvertisementTeksyte LTD

List Your Company

Showcase your company to thousands of pharma professionals.

Submit Listing

Advertise With Us

Reach decision-makers in the pharmaceutical industry.

Learn More

We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy